The two medications are being tested among patients with metabolic dysfunction-associated steatohepatitis, a liver disease not related to alcohol use that estimates say affects 0.05% of U.S. adults. In the study, 74% of patients taking tirzepatide, the active pharmaceutical ingredient of Mounjaro and Zepbound, achieved an absence of MASH with fibrosis remaining stable after a year.
Among those taking the placebo, that figure was 13%. The trial included 190 adults with MASH with severe stages of liver scarring, according to a CNBC report, and Eli Lilly will present more findings later this year.
The drugs also showed strong results for reducing blood pressure on top of helping patients shed weight.
In its 2023 fourth-quarter update, Eli Lilly said it sold $2.21 billion worth of its Type 2 diabetes drug Mounjaro and $175 million worth of Zepbound, a weight loss drug approved in November.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
